Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients

Zhao, Dongju; Xiao, Aiju; Tian, Ye; Zhang, Mingqiu

doi:10.12669/pjms.305.5170

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, drugs aimed at limiting angiogenesis have become increasingly studied in the treatment of various malignancies, including OS [ 116 - 117 ] . Vascular endothelial growth factor (VEGF) is one of the key regulators in angiogenesis and a well-studied marker associated with decreased disease-free survival in OS [ 118 - 121 ] . VEGF inhibitors have demonstrated considerable success in basic science and translational studies by reducing growth and metastatic potential of OS tumors, with the potential to sensitize cells to chemotherapy [ 122 - 126 ] .…”

Section: Emerging Therapies and Clinical Trialsmentioning

confidence: 99%

Molecular pathogenesis and therapeutic strategies of human osteosarcoma

Sahitya¹,

Denduluri²,

Zhongliang³

et al. 2016

J Biomed Res

View full text Add to dashboard Cite

Osteosarcoma (OS) is a devastating illness with rapid rates of dissemination and a poor overall prognosis, despite aggressive standard-of-care surgical techniques and combination chemotherapy regimens. Identifying the molecular mechanisms involved in disease pathogenesis and progression may offer insight into new therapeutic targets. Defects in mesenchymal stem cell differentiation, abnormal expression of oncogenes and tumor suppressors, and dysregulation within various important signaling pathways have all been implicated in development of various disease phenotypes. As such, a variety of basic science and translational studies have shown promise in identifying novel markers and modulators of these disease-specific aberrancies. Born out of these and similar investigations, a variety of emerging therapies are now undergoing various phases of OS clinical testing. They broadly include angiogenesis inhibitors, drugs that act on the bone microenvironment, receptor tyrosine kinase inhibitors, immune system modulators, and other radio- or chemo-sensitizing agents. As new forms of drug delivery are being developed simultaneously, the possibility of targeting tumors locally while minimizing systemic toxicityis is seemingly more achievable now than ever. In this review, we not only summarize our current understanding of OS disease processes, but also shed light on the multitude of potential therapeutic strategies the scientific community can use to make long-term improvements in patient prognosis.

show abstract

Section: Emerging Therapies and Clinical Trialsmentioning

confidence: 99%

Molecular pathogenesis and therapeutic strategies of human osteosarcoma

Sahitya¹,

Denduluri²,

Zhongliang³

et al. 2016

J Biomed Res

View full text Add to dashboard Cite

show abstract

Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer

Zhao

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

Investigation of the role of VEGF gene polymorphisms in the risk of osteosarcoma

Zhang¹,

Bai²,

Zhang³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a case-control study in a Chinese population, and assessed whether the VEGF -634G/C, +936C/T, and +1612G/A polymorphisms could affect the risk of osteosarcoma and its association with environmental factors. A total of 180 consecutive osteosarcoma patients and 360 controls were included in our study. The genotypes of VEGF -634G/C, +936C/T, and +1612G/A were determined by the polymerase chain reaction-restriction fragment length polymorphism assay. Conditional logistic regression analyses showed that subjects carrying the GG genotype and the G allele of VEGF -634G/C were significantly associated with increased risk of osteosarcoma compared to those with the CC genotype; the ORs (95%CIs) were 2.28 (1.31-3.96) and 1.51 (1.16-1.97) for the GG genotype and G allele, respectively. We found that the GG genotype of VEGF -634G/C was associated with a significantly increased risk 8284 G. Zhang et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 8283-8289 (2015) of osteosarcoma in patients of either gender with younger age and a family history of cancer. In summary, this study found that the VEGF -634G/C gene polymorphism was associated with an increased risk of osteosarcoma.

show abstract

Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients

Cited by 4 publications

References 0 publications

Molecular pathogenesis and therapeutic strategies of human osteosarcoma

Molecular pathogenesis and therapeutic strategies of human osteosarcoma

Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer

Investigation of the role of VEGF gene polymorphisms in the risk of osteosarcoma

Contact Info

Product

Resources

About